目的:寻找与非小细胞肺癌(NSCLC)相关的生物标志物有助于肺癌的诊断和精准治疗。血清M2-丙酮酸激酶(TuM2-PK)与肿瘤、癌胚抗原(CEA),和细胞角蛋白19片段(CYFRA21-1)和NSCLC进行分析。方法:血清TuM2-PK,CEA,和CYFRA21-1在184例NSCLC患者中,60例良性肺病(BLD)组,90例健康对照组(HC)。通过使用酶联免疫吸附测定来测量TuM2-PK的水平。CEA和CYFRA21-1的检测方法为电化学发光。绘制受试者工作特征(ROC)曲线评价TuM2-PK的诊断价值,CEA,和CYFRA21-1对NSCLC。采用Kaplan-Meier生存曲线评价不同血清TuM2-PK水平的NSCLC患者的生存状态。CEA,CYFRA21-1。结果:血清TuM2-PK水平,CEA,NSCLC组CYFRA21-1明显高于BLD组和HC组(P<0.01)。血清TuM2-PK,CEA,非小细胞肺癌患者CYFRA21-1与肿瘤淋巴结转移分期相关(P<0.05),淋巴结转移(P<0.05),远处转移(P<0.05)。ROC曲线显示血清TuM2-PK的曲线下面积,CEA,CYFRA21-1分别为0.814、0.638和0.719,上述3的组合为0.918。Kaplan-Meier存活曲线显示,TuM2-PK阳性的NSCLC患者3年和5年生存率,CEA,CYFRA21-1明显低于TuM2-PK阴性的NSCLC患者,CEA,和CYFRA21-1,分别(P<0.05)。结论:血清TuM2-PK,CEA,CYFRA21-1水平在NSCLC诊断中具有较高的临床价值,能有效判断患者的预后。
Objective: Finding biomarkers related to non-small cell lung cancer (NSCLC) is helpful for the diagnosis and precise treatment of lung cancer. The relationship between serum tumor M2-pyruvate kinase (TuM2-PK), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1) and NSCLC was analyzed. Methods: The serum levels of TuM2-PK, CEA, and CYFRA21-1 in 184 patients with the NSCLC group, 60 patients with the benign lung disease (BLD) group, and 90 healthy controls (HC) group were detected. The levels of TuM2-PK were measured by using an enzyme-linked immunosorbent assay. The detection methods of CEA and CYFRA21-1 were electrochemiluminescence. The receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of TuM2-PK, CEA, and CYFRA21-1 on NSCLC. The Kaplan-Meier survival curve was drawn to evaluate the survival status in NSCLC patients with different serum levels of TuM2-PK, CEA, and CYFRA21-1. Results: Serum levels of TuM2-PK, CEA, and CYFRA21-1 in the NSCLC group were significantly higher than those in the BLD group and the HC group (P < .01). Serum levels of TuM2-PK, CEA, and CYFRA21-1 in NSCLC patients were associated with the tumor lymph node metastasis stage (P < .05), lymph node metastasis (P < .05), and distant metastasis (P < .05). The ROC curve showed that the area under the curve of serum levels of TuM2-PK, CEA, and CYFRA21-1 was 0.814, 0.638, and 0.719, respectively, and that the combination of the above 3 was 0.918. The Kaplan-Meier survival curve showed that the 1-, 3- and 5-year survival rate in NSCLC patients with positive TuM2-PK, CEA, and CYFRA21-1 was significantly lower than that in NSCLC patients with negative TuM2-PK, CEA, and CYFRA21-1, respectively (P < .05). Conclusions: Serum TuM2-PK, CEA, and CYFRA21-1 levels have high clinical values in the diagnosis of NSCLC, and can effectively judge the prognosis of patients.